WO2006014683A3 - Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2 - Google Patents

Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2 Download PDF

Info

Publication number
WO2006014683A3
WO2006014683A3 PCT/US2005/025656 US2005025656W WO2006014683A3 WO 2006014683 A3 WO2006014683 A3 WO 2006014683A3 US 2005025656 W US2005025656 W US 2005025656W WO 2006014683 A3 WO2006014683 A3 WO 2006014683A3
Authority
WO
WIPO (PCT)
Prior art keywords
glycoform
immunoglobulins
predominantly
relates
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/025656
Other languages
English (en)
Other versions
WO2006014683A2 (fr
Inventor
Tillman U Gerngross
Huijuan Li
Stefan Wildt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlycoFi Inc
Original Assignee
GlycoFi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlycoFi Inc filed Critical GlycoFi Inc
Priority to JP2007522676A priority Critical patent/JP2008515772A/ja
Priority to CA002573842A priority patent/CA2573842A1/fr
Priority to EP05790299A priority patent/EP1771477A2/fr
Priority to AU2005269763A priority patent/AU2005269763A1/en
Publication of WO2006014683A2 publication Critical patent/WO2006014683A2/fr
Publication of WO2006014683A3 publication Critical patent/WO2006014683A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne des compositions de glycoprotéines d'immunoglobulines présentant des structures N- glycane prédominantes sur une glycoprotéine d'immunoglobuline conférant une fonction effectrice spécifique. L'invention concerne également des compositions pharmaceutiques contenant un anticorps présentant une structure N- glycane caractéristique enrichie, ladite structure N glycane étant une glycoforme Gal2GlcNAc2Man3GlcNAc2.exempte de fucose.
PCT/US2005/025656 2004-07-21 2005-07-19 Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2 Ceased WO2006014683A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2007522676A JP2008515772A (ja) 2004-07-21 2005-07-19 Ｇａｌ２ＧｌｃＮＡｃ２Ｍａｎ３ＧｌｃＮＡｃ２グリコフォームを支配的に含む免疫グロブリン
CA002573842A CA2573842A1 (fr) 2004-07-21 2005-07-19 Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2
EP05790299A EP1771477A2 (fr) 2004-07-21 2005-07-19 Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2
AU2005269763A AU2005269763A1 (en) 2004-07-21 2005-07-19 Immunoglobulins comprising predominantly a Gal2GlcNac2Man3GlcNac2 glycoform

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59005204P 2004-07-21 2004-07-21
US59003004P 2004-07-21 2004-07-21
US60/590,030 2004-07-21
US60/590,052 2004-07-21

Publications (2)

Publication Number Publication Date
WO2006014683A2 WO2006014683A2 (fr) 2006-02-09
WO2006014683A3 true WO2006014683A3 (fr) 2006-06-08

Family

ID=35502713

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/025656 Ceased WO2006014683A2 (fr) 2004-07-21 2005-07-19 Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2

Country Status (5)

Country Link
EP (1) EP1771477A2 (fr)
JP (1) JP2008515772A (fr)
AU (1) AU2005269763A1 (fr)
CA (1) CA2573842A1 (fr)
WO (1) WO2006014683A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877462B2 (en) 2000-06-28 2014-11-04 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8986949B2 (en) 2003-02-20 2015-03-24 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
WO2008008482A2 (fr) * 2006-07-13 2008-01-17 Genentech, Inc. Polypeptides de liaison à br3 modifiés
NZ576032A (en) 2006-10-12 2012-03-30 Genentech Inc Antibodies to lymphotoxin-alpha
MX2010013059A (es) 2008-05-30 2010-12-20 Glycofi Inc Cepa de levadura para la produccion de proteinas con galactosa alfa-1,3-enlazada terminal.
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
US8458171B2 (en) 2009-01-30 2013-06-04 Google Inc. Identifying query aspects
EP2401378B1 (fr) * 2009-02-25 2013-08-14 Merck Sharp & Dohme Corp. Ingénierie métabolique d'une voie d'assimilation du galactose dans la levure glycosynthétisée pichia pastoris
WO2012149197A2 (fr) 2011-04-27 2012-11-01 Abbott Laboratories Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
EP2741769B1 (fr) * 2011-08-10 2019-01-02 Laboratoire Français du Fractionnement et des Biotechnologies Anticorps fortement galactosylés
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20160002713A (ko) 2013-02-13 2016-01-08 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 고도로 갈락토실화된 항-tnf-알파 항체 및 이의 용도
EP2956003A2 (fr) 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Protéines à glycosylation modifiée et leurs procédés de production
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (fr) 2013-03-14 2014-09-25 Abbvie Inc. Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003056914A1 (fr) * 2001-12-27 2003-07-17 Glycofi, Inc. Procede d'ingenierie de structures de carbohydrates de type mammalien

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003056914A1 (fr) * 2001-12-27 2003-07-17 Glycofi, Inc. Procede d'ingenierie de structures de carbohydrates de type mammalien

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOBROWICZ P ET AL: "Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose", GLYCOBIOLOGY, IRL PRESS,, GB, vol. 14, no. 9, 9 June 2004 (2004-06-09), pages 757 - 766, XP002354412, ISSN: 0959-6658 *
HAMILTON S R ET AL: "Production of complex human glycoproteins in yeast", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 301, no. 5637, 29 August 2003 (2003-08-29), pages 1244 - 1246, XP002267832, ISSN: 0036-8075 *
ROUTIER FRANCOISE H ET AL: "The glycosylation pattern of a humanized IgGI antibody (D1.3) expressed in CHO cells", GLYCOCONJUGATE JOURNAL, vol. 14, no. 2, 1997, pages 201 - 207, XP002375244, ISSN: 0282-0080 *
SCHWIENTEK TILO ET AL: "Golgi localization and in vivo activity of a mammalian glycosyltransferase (human beta-1,4-galactosyltransferase) in yeast", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 7, 1996, pages 3398 - 3405, XP002375245, ISSN: 0021-9258 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877462B2 (en) 2000-06-28 2014-11-04 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8883483B2 (en) 2000-06-28 2014-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8986949B2 (en) 2003-02-20 2015-03-24 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes

Also Published As

Publication number Publication date
EP1771477A2 (fr) 2007-04-11
WO2006014683A2 (fr) 2006-02-09
JP2008515772A (ja) 2008-05-15
CA2573842A1 (fr) 2006-02-09
AU2005269763A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
WO2006071856A3 (fr) Immunoglobulines comprenant principalement une glycoforme man5glcnac2
WO2006066568A3 (fr) Anticorps
WO2008079995A3 (fr) Conjugué comprenant un peptide natriurétique et une région constante d'un anticorps
WO2007147122A3 (fr) Anticorps monoclonaux qui reconnaissent sélectivement des composés de méthamphétamine et de type méthamphétamine
IL184152A (en) Monoclonal antibodies against nkg2a, preparations containing them, their use in drug preparation, methods of manufacture, and methods used in
WO2007129895A3 (fr) Anticorps monoclonal antagoniste anti-cd40 humain
WO2008091798A3 (fr) Anticorps de ca9 optimises et methodes d'utilisation associees
WO2007057773A3 (fr) Composes photoactifs
WO2008022152A3 (fr) Anticorps optimisés ciblant cd19
WO2006094192A3 (fr) Anticorps humanises l243
WO2006104989A3 (fr) Anticorps a regions fc modifiees et utilisations
WO2008091954A3 (fr) Anticorps cd40 optimisés et leurs procédés d'utilisation
IL222756A0 (en) Antibodies and antigen-binding fragments thereof that bind to a sclerostin polypeptide, compositions containing the same and methods for the production thereof
WO2008098115A3 (fr) Anti-corps igf-1r optimisés et procédés utilisant ceux-ci
WO2008046641A3 (fr) Implant enduit
WO2006050280A3 (fr) Anticorps et antigenes anti-virus respiratoire syncytial et leurs utilisations
WO2007028144A3 (fr) Immunoglobulines comprenant principalement une glycoforme glcnacman3glcnac2
WO2006021955A3 (fr) Utilisation d'anticorps monoclonaux bat pour l'immunotherapie
WO2007050569A3 (fr) Films de polypeptide multicouches et procedes
AU2003233992A1 (en) Functional element for attaching to a sheet metal part, composite component produced from said element and method for attaching the functional element to a sheet metal part
WO2005074970A3 (fr) Complément alimentaire neuroprotecteur
WO2004004639A3 (fr) Nouvelle formulation stable
WO2005076013A3 (fr) Processus de criblage d'anticorps specifiques contre des glycoformes
WO2004075021A3 (fr) Procedes de modelisation moleculaire
WO2006014726A3 (fr) Immunoglobulines comprenant principalement une glycoforme man5glcnac2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2573842

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005790299

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007522676

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200580024664.0

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005269763

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1206/DELNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005269763

Country of ref document: AU

Date of ref document: 20050719

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005269763

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005790299

Country of ref document: EP